icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Inclusion
Clinical Benefit
Substantial
the actual benefit of HEMANGIOL 3.75 mg/ml oral solution is substantial in the indication in the Marketing Authorisation.
Clinical Added Value
moderate
HEMANGIOL 3.75 mg/ml oral solution provides a moderate improvement in actual benefit (IAB III) in the treatment of proliferating infantile haemangioma requiring systemic therapy.
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
GNXa2b5UrpKhWbBZ